The Weekly Recap 8/29/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funds, receive regulatory approvals, and much more on the road to LSI Europe ’25 in London (September 7–11).

AVASA

Completed the first close of an oversubscribed Pre-Series A round led by Movac, raising NZD$4.75M to advance its category-defining AVASA Coupler device. The funding enables Avasa to complete FDA clearance and prepare for the commercial launch of its microsurgical solution for standardized arterial reconnection.

Ciliatech

Received CE mark approval for Intercil, a uveal spacer eye implant that treats glaucoma via a novel cilioscleral interpositioning approach. The implant aims to preserve anterior chamber integrity using a “no-bleb-no-cleft” method and is now set for commercial rollout across Europe with future expansion into the U.S. and China.

Facet Dynamics

Secured private equity funding to support regulatory efforts, including a pivotal, multi-center national IDE clinical study for its Restore “artificial back joint.” The funding removes regulatory risk for potential acquirers and sets a clear path to bring the novel facet joint replacement system to U.S. patients.

GT Medical Technologies

Treated its 2,000th patient with GammaTileⓇ, a bioresorbable implant that delivers localized radiation therapy immediately after brain tumor removal. The milestone highlights growing adoption across more than 200 leading cancer centers and reinforces the therapy’s impact in closing the treatment gap between surgery and radiation.

Light Line Medical

Was accepted into the FDA’s Safer Technologies Program for its light-based infection-prevention platform. The designation validates the potential impact of Light Line’s PhotoDisinfection™ System for catheter-associated infection prevention and supports a more efficient path to market.

Optheras

Raised $6M from existing shareholders to initiate its first clinical study for a laser-based treatment for superficial bladder tumors. The funds will support development of the company’s anesthesia-free, office-based procedure and builds on the recent FDA Breakthrough Device Designation for its laser and disposable fiber system.

PAVmed

Announced plans to license a novel endoscopic imaging technology from Duke University to detect and treat advanced esophageal precancer during upper endoscopy. The agreement adds a/LCI+OCT technology to its portfolio and strengthens its position in the esophageal precancer space.

Planatome

Promoted Keith Jeffcoat as President and Chief Innovation Officer and appointed Bill Fender and Matt Likens to its Executive Board. The leadership expansion strengthens Planatome’s focus on innovation and strategic growth as it advances adoption of its patented nano-polishing platform.

Plexāā

Joined Johnson & Johnson Innovation’s JLABS EMEA as a virtual member to accelerate development of BLOOM43, a wearable device that enables supraphysiological preconditioning™ before breast surgery. The milestone supports the company’s mission to reduce wound healing complications and expand its platform into additional surgical applications.


This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-82925-lsi-alumni-achievements-driving-medtech-and-healthtech-forward 

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more